It is also of interest to determine whether the same combination of TLR agonists is useful for improving the ex vivo expansion efficacy of other types of therapeutic human T cells, including but not limited to tumor infiltrating CD8+ T cells and CAR-T cells. This evidence concerns the gene CD8A and neoplasm.